Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.4130
    +0.1670 (+0.11%)
     
  • Bitcoin USD

    70,860.52
    +1,441.79 (+2.08%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN

NEW YORK, NY / ACCESSWIRE / April 25, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Myriad Genetics, Inc. (MYGN) from August 13, 2014 through March 12, 2018, inclusive. The lawsuit seeks to recover damages for Myriad investors under the federal securities laws.

To join the Myriad class action, go to http://pawarlawgroup.com/cases/myriad-genetics-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for Myriad's hereditary cancer testing; (2) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (3) Myriad's revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (4) as a result, Myriad's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 19, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/myriad-genetics-inc/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar, Esq. of Pawar Law Group toll-free at 888-589-9804 or via e-mail at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll-Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group

Advertisement